<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Activation of the Raf/MEK/ERK (MAPK) signal transduction cascade by <z:mp ids='MP_0011356'>RAS</z:mp> mutations has been found in a variety of human <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Mutations of BRAF provide an alternative route for activation of this signalling pathway </plain></SENT>
<SENT sid="2" pm="."><plain>To determine the role of mutations in BRAF and KRAS2 in the <z:e sem="disease" ids="C0178874" disease_type="Neoplastic Process" abbrv="">neoplastic progression</z:e> of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp>, we analysed both genes for common mutations </plain></SENT>
<SENT sid="3" pm="."><plain>After microdissection, DNA of 19 Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, 56 Barrett's intraepithelial <z:hpo ids='HP_0002664'>neoplasias</z:hpo> (n=29 low-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (LGIN) and n=27 high-grade intraepithelial <z:hpo ids='HP_0002664'>neoplasia</z:hpo> (HGIN)), 30 Barrett's mucosa without <z:hpo ids='HP_0002664'>neoplasia</z:hpo> and <z:mpath ids='MPATH_458'>normal</z:mpath> squamous, as well as gastric epithelium, were analysed for BRAF and KRAS2 mutation </plain></SENT>
<SENT sid="4" pm="."><plain>Activating BRAF mutations were identified in 2/19 Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> (11%) and in 1/27 HGIN (4%) </plain></SENT>
<SENT sid="5" pm="."><plain>KRAS2 mutations were found in four out of 19 (21%) Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> examined and in three cases of HGIN (11%) </plain></SENT>
<SENT sid="6" pm="."><plain>In LGIN as well as in <z:mpath ids='MPATH_458'>normal</z:mpath> gastric or oesophageal mucosa, neither BRAF nor KRAS2 mutations were detected </plain></SENT>
<SENT sid="7" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> lesions with KRAS2 mutations had an intact BRAF gene </plain></SENT>
<SENT sid="8" pm="."><plain>The status of mismatch-repair proteins was neither related to BRAF nor KRAS2 mutations </plain></SENT>
<SENT sid="9" pm="."><plain>These data indicate that <z:mp ids='MP_0011356'>RAS</z:mp> or BRAF mutations are detected in about 32% of <z:hpo ids='HP_0000001'>all</z:hpo> Barrett's <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="10" pm="."><plain>We conclude that the disruption of the Raf/MEK/ERK (MAPK) kinase pathway is a frequent but also early event in the development of Barrett's <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> </plain></SENT>
</text></document>